HematologyNews.net

Hematology Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Farmaexplorer.it

New data from Cohort 3 of the phase 2 REFINE study of investigational Navitoclax in combination with Ruxolitinib in JAK inhibitor naïve patients with myelofibrosis ( MF ), a rare blood cancer, were an ...


Primary results from the large B-cell lymphoma ( LBCL ) expansion cohort in the EPCORE NHL-1 phase 2 clinical trial evaluating Epcoritamab ( DuoBody-CD3xCD20 ), an investigational subcutaneous bispeci ...


Momelotinib ( MMB ), an oral JAK1/2 and ACVR1/ALK2 inhibitor, has shown clinical activity on myelofibrosis symptoms, red blood cell ( RBC ) transfusion requirements ( anemia ), and spleen volume in th ...


Treatment of polycythemia vera aims to prevent thromboembolic complications, reduce the risk of progression to acute leukemia or myelofibrosis, and ameliorate the symptom burden; specifically, to impr ...


Brexucabtagene autoleucel ( KTE-X19; Brexu-cel; Tecartus ) is an autologous anti-CD19 chimeric antigen receptor ( CAR ) T-cell therapy approved for the treatment of patients with relapsed / refractory ...


Teclistamab is a BCMA × CD3 T-cell redirecting bispecific antibody under investigation in patients with relapsed / refractory multiple myeloma ( RRMM ). Daratumumab ( Darzalex Faspro) is a CD38 mono ...


Belantamab mafodotin ( Belamaf; Blenrep ), a B-cell maturation antigen ( BCMA ) targeted antibody-drug conjugate approved for adult patients with relapsed / refractory multiple myeloma, has a multimod ...


The results from the ZUMA-12 trial led by researchers at The University of Texas MD Anderson Cancer Center have shown that first-line treatment with Axicabtagene ciloleucel ( Axi-cel; Yescarta ), a ch ...


On the basis of the DREAMM-2 study, single-agent Belantamab mafodotin ( Belamaf; Blenrep ) was approved for patients with relapsed or refractory multiple myeloma ( RRMM ) who received 4 or more prior ...


In patients with transplant-ineligible newly diagnosed multiple myeloma ( NDMM ), Daratumumab ( Darzalex ) has reduced the risk of disease progression or death by 44% in MAIA ( Daratumumab / Lenalidom ...


A phase 1-2 study evaluated Brentuximab vedotin ( Adcetris ) combined with Nivolumab ( Opdivo ) as first salvage therapy in patients with relapsed/refractory ( r/r ) classical Hodgkin lymphoma ( cHL ...


Myelofibrosis symptoms compromise health-related quality of life ( HRQoL ). Ruxolitinib can reduce myelofibrosis symptom severity, but many patients discontinue Ruxolitinib due to loss of response or ...


Low-density lipoprotein ( LDL ) receptor-related protein-associated protein 1 ( LRPAP1 ) had been identified by B-cell receptor ( BCR ) expression cloning and subsequent protein array screening as a f ...


Tafasitamab, an Fc-modified, humanized, anti-CD19 monoclonal antibody, combined with the immunomodulatory drug Lenalidomide ( Revlimid ), was clinically active with a good tolerability profile in the ...


Low-density lipoprotein ( LDL ) receptor-related protein-associated protein 1 ( LRPAP1 ) had been identified by B-cell receptor ( BCR ) expression cloning and subsequent protein array screening as a f ...